UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000004282
Receipt No. R000005082
Scientific Title Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy :A Placebo-controlled Double-blind Randomized Phase III Study
Date of disclosure of the study information 2010/10/01
Last modified on 2015/02/02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy :A Placebo-controlled Double-blind Randomized Phase III Study
Acronym Goshajinkigan Effect for oxaliplatin Neurotoxicity Inhibition USing mFOLFOX6 regimen(GENIUS)
Scientific Title Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy :A Placebo-controlled Double-blind Randomized Phase III Study
Scientific Title:Acronym Goshajinkigan Effect for oxaliplatin Neurotoxicity Inhibition USing mFOLFOX6 regimen(GENIUS)
Region
Japan

Condition
Condition Colorectal cancer
Classification by specialty
Medicine in general Gastroenterology Hematology and clinical oncology
Surgery in general Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The aim of this study is to evaluate benefit of Kampo-goshajinkigan as a supportive therapy for chemo-induced peripheral neuropathy (CIPN) in postoperative mFOLFOX6 adjuvant chemotherapy for p-Stage III colorectal cancer patient in comparison with placebo (Phase III study).
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase III

Assessment
Primary outcomes TimeToGrade2+ (CTCAE v4.0) Neuropathy; TTN
Key secondary outcomes L-OHP dose intensity DI
safety

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification YES
Dynamic allocation YES
Institution consideration Institution is considered as adjustment factor in dynamic allocation.
Blocking NO
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Goshajinkigan 7.5g/day, 12 course + mFOLFOX6 12 course
Interventions/Control_2 Placebo 7.5g/day, 12 course + mFOLFOX6 12 course
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria 1)Written informed consent
2)Patients who is judged by investigator to be able to receive the protocol therapy
3)Patients with histologically proven colorectal cancer and lower edge of tumor located upper than Douglas pouch
4)p-Stage IIIa /IIIb
5)R0 (Curability A)
6)Age; 20<=, <=80
7)ECOG performance status 0-1
8)within 8 weeks from operation
9) Patiens have enough organ function based on blood test
1.WBC>=3,000-<=12,000/mm3, 2.Neurtophils>=1,500/mm3
3. Platelets>=100,000/mm3
4. Hemoglobin>=9.0g/dl
5. Total bilirubin<=2.0mg/dl
6.AST<=100U/L
7.ALT<=100U/L
8. Creatinine<=1.5mg/dl
Key exclusion criteria 1)transfusion, G-CSF etc. within 7days
2)severe allergic reaction
3)peripheral neuropthy
4)Simultaneous or metachronous double cancers
5)Active infectious disease
6)Severe mental disease
7)Grade2+, diarrhea
8)systemic administration of corticosteroids
9)Pregnant or lactating women or women of childbearing potential
10)Severe comorbidity (interstitial peumonitis, lung fibrosis, paralytic ileus, mechanical ileus, uncontrollable diabetes, liver cirosis, chronic hepatitis, career with hepatitis B/C, renal failure, heart failure, uncontrollable hypertension, unstable angina etc)
11)AMI within 6 months
12)History of transplantation
13)Preoperative therapy for CRC
14)History of colostomy
15)Unhealing of post-operative complication
16)Gashajinkigan, or drug for neuropathy
17)Any other cases who are regarded as inadequate for study enrollment by the investigator
Target sample size 310

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yoshihiro Kakeji
Organization Graduate School of Medicine, Kobe University
Division name Division of Gastrointestinal Surgery, Department of Surgery
Zip code
Address 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, JAPAN
TEL 078-382-5925
Email kakeji@med.kobe-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Satomi Abe
Organization Graduate School of Medical Sciences, Kyushu University
Division name Department of Surgery and Science
Zip code
Address Maidashi 3-1-1, Higashi-ku, Fukuoka
TEL 092-642-5466
Homepage URL
Email abesato@surg2.med.kyushu-u.ac.jp

Sponsor
Institute Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University
Institute
Department

Funding Source
Organization Ministry of Health, Labour and Welfare (Japan)
Organization
Division
Category of Funding Organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor EPS Co., Ltd.
TSUMURA & CO.
YAMATO LOGISTICS CO,. LTD.
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 九州大学病院(福岡県)、鳥取大学病院(鳥取県)、埼玉医科大学総合医療センター(埼玉県)、広島大学病院(広島県)、久留米大学医学部附属医療センター(福岡県)、箕面市立病院(大阪府)、獨協医科大学病院(栃木県)、国立病院機構米子医療センター(鳥取県)、横浜市立大学附属市民総合医療センター(神奈川県)、群馬大学医学部附属病院(群馬県)、旭川医科大学病院(北海道)、金沢医科大学病院(石川県)、愛知県がんセンター愛知病院(愛知県)、名古屋大学医学部附属病院(愛知県)、高知大学医学部附属病院(高知県)、関西医科大学病院(大阪府)、浜松医科大学医学部附属病院(静岡県)、京都大学医学部附属病院(京都府)、九州がんセンター(福岡県)、徳島大学病院(徳島県)、久留米大学病院(福岡県)、大阪医科大学附属病院(大阪府)、千葉県がんセンター(千葉県)、岐阜市民病院(岐阜県)、兵庫医科大学病院(兵庫県)、川崎医科大学附属病院(岡山県)、長崎大学病院(長崎県)、鹿児島大学病院(鹿児島県)、琉球大学医学部附属病院(沖縄県)、金沢赤十字病院(石川県)、弘前大学医学部附属病院(青森県)、熊本大学医学部附属病院(熊本県)、大阪市立大学医学部附属病院(大阪府)、日本大学病院(東京都)、岡山大学病院(岡山県)、札幌医科大学附属病院(北海道)、藤田保健衛生大学病院(愛知県)、東北大学病院(宮城県)、愛知県がんセンター中央病院(愛知県)、大阪大学医学部附属病院(大阪府)、青森県立中央病院(青森県)、福井大学医学部附属病院(福井県)、岐阜大学医学部附属病院(岐阜県)、北里大学病院(東京都)、国立病院機構別府医療センター(大分県)、関西労災病院(兵庫県)、日本医科大学附属病院(東京都)

Other administrative information
Date of disclosure of the study information
2010 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Int J Clin Oncol. 2015 Jan 28. [Epub ahead of print]
PMID:25627820[PubMed - as supplied by publisher] 
Related citations 
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2010 Year 08 Month 12 Day
Date of IRB
Anticipated trial start date
2010 Year 10 Month 01 Day
Last follow-up date
2013 Year 09 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2010 Year 09 Month 28 Day
Last modified on
2015 Year 02 Month 02 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005082

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.